Synthesis and biological properties of oxazolinodaunorubicin-a new derivative of daunorubicin with a modified daunosamine moiety

Investigational New Drugs

Volumn 28, Issue 5, 2010, Pages 600-608

  Lukawska, Malgorzata ^a   Wietrzyk, Joanna ^b   Opolski, Adam ^b   Oszczapowicz, Janusz ^c   Oszczapowicz, Irena ^a  

^a INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^c UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cardiotoxicity; Cytotoxicity; Daunorubicin derivative; Drug resistance; Transplantable murine tumors

Indexed keywords

DAUNORUBICIN; DAUNORUBICIN DERIVATIVE; FORMAMIDINODAUNORUBICIN; OXAZOLINODAUNORUBICIN; UNCLASSIFIED DRUG; DAUNOSAMINE; HEXOSAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CARDIOTOXICITY; COLON CARCINOMA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RESISTANCE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LD 50; LEUKEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; SURVIVAL; SYNTHESIS; TIME; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DAUNORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HEXOSAMINES; HUMANS; LETHAL DOSE 50; MALE; MICE; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 77956059832     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9299-4     Document Type: Article

References (21)

1. F Kratz R Muller-Driver I Hoffman J Drevs C Ungrer 2000 A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy J Med Chem 43 1253 1256 10.1021/jm.9905864 10.1021/jm9905864 1:CAS:528:DC%2BD3cXhsFyhtLw%3D 10753462
2. J Nadas D Sun 2006 Anthracyclines as effective anticancer drugs Expert Opin Drug Discov 1 6 1 20 10.1517/17460441.1.6.549 10.1517/17460441.1.6.549
3. L Fang G Zhang C Li 2006 Synthesis and biological activities of 3'-azidodissacharide analogues of daunorubicin against drug-resistant leukemia J Med Chem 49 932 941 10.1021/jm050800q 1:CAS:528:DC%2BD28XitVCrtw%3D%3D 16451059
4. G Minotti P Menna E Salvatorelli G Cairo L Guan 2004 Anthracycline activity and cardiotoxicity Pharmacol Rev 56 185 229 10.1124/pr.56.2.6 1:CAS:528:DC%2BD2cXltlKgtb0%3D 15169927
5. SM Cutts LP Swift V Pillay RA Forrest, et al. 2007 Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate Mol Cancer Ther 6 4 1450 1459 10.1158/1535-7163.MCT- 06-0551 10.1158/1535-7163.MCT-06-0551 1:CAS:528:DC%2BD2sXktFamsLo%3D 17431124
6. Oszczapowicz I, Wa̧sowska M, Oszczapowicz J, Dominiczak E, Owoc A, Opolski A, Wietrzyk J (2005) Nowe pochodne antybiotyków antracyklinowych oraz zawieraja̧cy je środek farmaceutyczny. Polish Patent Appl P 381397
7. M Wasowska I Oszczapowicz J Wietrzyk A Opolski J Madej S Dzimira J Oszczapowicz 2005 Influence of the structure of new anthracycline antibiotics on their biological properties Anticancer Res 25 2043 2048 1:CAS:528: DC%2BD2MXmtl2htb8%3D 16158943
8. M Wasowska J Wietrzyk A Opolski J Oszczapowicz I Oszczapowicz 2006 Effect of structural modification of anthracyclines against drug-sensitive and resistant cancer cells Anticancer Res 26 2009 2012 1:CAS:528: DC%2BD28XntV2nuro%3D 16827137
9. M Wasowska-Lukawska J Wietrzyk A Opolski J Oszczapowicz I Oszczapowicz 2007 Biological properties of new derivatives of daunorubicin In Vivo 21 2 413 416 1:CAS:528:DC%2BD2sXkslyltbY%3D 17436596
10. E Ciesielska K Studzian M Wasowska I Oszczapowicz L Szmigiero 2005 Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety Cell Biol Toxicol 21 139 147 10.1007/s10565-005-0142-1 1:CAS:528:DC%2BD2MXht1ensbfL 16328893
11. RF Abdulla RS Brinkmeyer 1979 The chemistry of formamide acetals Tetrahedron 35 14 1675 1735 10.1016/0040-4020(79)88001-1 10.1016/0040-4020(79) 88001-1 1:CAS:528:DyaL3cXksVGrtrg%3D
12. P Skehan R Storeng D Skudiero A Monks J McMahon D Vistica JT Warren, et al. 1990 New colorimetric cytotoxicity assay for anticancer-drug screening J Natl Cancer Inst 82 1107 1112 10.1093/jnci/82.13.1107 1:CAS:528: DyaK3cXltVylsL8%3D 2359136
13. E Marcinkowska A Kutner C Radzikowski 1998 Cell differentiating and antiproliferative activity of side-chain modified analogues of 1, 25-dihydroxyvitamin D3 J Steroid Biochem Molec Biol 67 71 78 10.1016/S0960-0760(98)00065-X 1:CAS:528:DyaK1cXmsV2hu7k%3D 9780032
14. WG Harker WS Slade PS Meltzer JM Trent 1989 Multidrug resistance in mitoxantrone HL leukemia cells in the absence of P-glycoprotein overexpression Cancer Res 49 4542 4549 1:CAS:528:DyaL1MXlt1Kmur8%3D 2568172
15. DR Waud 1972 On biological assays involving quantal responses J Pharmacol Exp Ther 183 577 583 1:STN:280:DyaE3s%2FkvVOhsQ%3D%3D 4636393
16. Armitage P, Bregg G (1985) Statistical methods in medical research. Blackwell, London
17. M Nowak S Suomi 1989 Perspectives in animals. Guidelines for the welfare of animals in experimental neoplasia ILAR J Online 31 3 1 9
18. J Vendetti 1984 Current NCI preclinical antitumor screening in vivo: result of tumor panel screening 1976-1982 and future directions Adv Pharmacol Chemother 20 1 20 10.1016/S1054-3589(08)60263-X
19. Experimental Therapeutic Program (1984) In vivo cancer models, 1976-1982. Bethesda. MD: NIH Publication No. 84-2635
20. R Geran N Greenberg M Mac Donald A Schumacher B Abbot 1972 Protocols for screening of chemical agents and natural products against animal tumors and their biological systems Cancer Chemoth Rep 3 2 51 61
21. Wasowska M, Wietrzyk J, Opolski A, Oszczapowicz I, Oszczapowicz J (2005) In vivo activity of new derivatives of anthracycline antibiotics. Medimond Intern. Proceeding, F620C0154, p 81-84